Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 3 (2021)
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy | Annals of Surgical Oncology
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
RAS mutations: impact on treatment outcome | Colorectal Cancer
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
The Trouble With KRAS - Cancer Commons
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Promising results for a new bowel cancer treatment
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis - The Lancet Oncology
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted? - CancerConnect
Life | Free Full-Text | Integrated Decision-Making in the Treatment of Colon -Rectal Cancer: The Case of KRAS-Mutated Tumors
KRAS testing is a screening of non-responders to anti-EGFR therapy.... | Download Scientific Diagram
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Colorectal Cancer
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
